# OncoHost

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncohost

- Industry: Biotechnology
- Headquarters: Israel
- Website: www.oncohost.com/
- Total disclosed funding: $43M
- Latest round: Series C (May 10, 2022)
- Investors on record: 4

## About

OncoHost, Inc. is an innovative company based in Israel, specializing in precision oncology solutions through its advanced PROphet® platform, which employs artificial intelligence for personalized cancer treatment predictions.Founded in 2017, OncoHost, Inc. focuses on precision oncology, offering services that analyze patient samples to improve cancer treatment strategies. The company, led by founder Yuval Shaked, has raised a total of EUR 35.00 mn across multiple funding rounds. Their most recent funding, a GRANT of EUR 2.5 mn from Horizon Europe, was secured on May 15, 2025, aimed at accelerating ongoing cancer treatment research.OncoHost specializes in precision oncology solutions, primarily through its flagship product, the PROphet® platform. This innovative system leverages bioinformatic proteomic pattern recognition and artificial intelligence to generate personalized PROphet® scores, which predict the efficacy of PD-1/PD-L1 inhibitors for cancer treatment. The testing process involves analyzing plasma or serum samples taken from patients before they start therapy, providing insights into tumor biology and host microenvironment interactions. By focusing on resistance mechanisms in immunotherapy for lung cancer and other malignancies, OncoHost aims to enhance clinical decision-making and patient outcomes. The company's products are primarily utilized by healthcare providers, oncologists, and researchers across North America, Europe, and Asia.Revenue generation for OncoHost is primarily derived from its diagnostic testing services, specifically through the PROphet® test and the developing NeutroFlow test, which guides cancer therapy selection. The company operates on a direct-to-consumer model, where healthcare providers can order tests for their patients, leading to subsequent analysis and reporting services. Transactions are structured as service fees charged per test conducted, with potential subscription models for healthcare institutions seeking ongoing access to OncoHost's proprietary analytics and insights. The company targets oncologists and cancer treatment centers as its primary client base, providing them with actionable data that informs treatment strategies.OncoHost plans to utilize the EUR 2.5 mn grant funding received from Horizon Europe in May 2025 to accelerate its research on cancer treatments. The company is expected to design and launch new products, enhancing its existing offerings in precision oncology. Furthermore, OncoHost is looking to expand its operations into new markets, specifically targeting additional regions across North America and Europe by the end of 2025.

## Funding rounds

- Series C, May 10, 2022, $35M — Menora Mivtachim Group, Leumi Partners, OurCrowd, ALIVE
- Series B, Jan 19, 2021, $8M — OurCrowd

## Investors

- OurCrowd (https://capitalatlas.ai/funds/ourcrowd) — Series B, Series C
- Menora Mivtachim Group — Series C
- Leumi Partners — Series C
- ALIVE — Series C